Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a Houston-based clinical-stage biopharmaceutical company established in 2017. The company is dedicated to developing novel anticancer drug candidates aimed at treating primary and metastatic cancers of the brain and central nervous system (CNS). Their lead drug candidate, Berubicin, is a pioneering anthracycline that distinguishes itself by its ability to cross the blood-brain barrier, offering new hope for patients suffering from glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer.
Berubicin has shown promise in initial trials, with the Phase I clinical trial completing successfully. As of now, Berubicin is being evaluated in a potentially pivotal study. The preliminary safety data was presented at the Society of NeuroOncology (SNO) 28th Annual Meeting, highlighting its comparability in patient demographics and safety with the control arm of the study. Encouragingly, the independent Data Safety Monitoring Board (DSMB) recommended the continuation of the trial without modification after a pre-planned interim futility analysis, signifying Berubicin’s acceptable efficacy and safety profile.
The company has also secured several important collaborations and licensing agreements, including partnerships with Houston Pharmaceuticals, Inc., the University of Texas M.D. Anderson Cancer Center, and WPD Pharmaceuticals Inc. These agreements bolster the development pipeline and provide access to cutting-edge research and development facilities.
Financially, CNS Pharmaceuticals is proactive in securing necessary funding for their research endeavors. Recent public offerings and strategic financial management have ensured operational continuity and support for their ongoing clinical trials. Despite the inherent risks and uncertainties of drug development, CNS Pharmaceuticals remains steadfast in their mission to develop effective cancer therapies.
Beyond Berubicin, CNS Pharmaceuticals continues to explore additional drug candidates and therapies to address various CNS oncology indications. The company's commitment to innovation and patient care positions it as a potential leader in the fight against some of the most challenging cancer types.
For more information, please visit www.CNSPharma.com and connect with the company on Twitter, Facebook, and LinkedIn.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has regained compliance with Nasdaq's equity requirement. The company received notice from Nasdaq on September 10, 2024, confirming its compliance with Listing Rule 5550(b)(1). This development is subject to a one-year Nasdaq Mandatory Panel Monitor related to the equity requirement. With this compliance issue resolved, Nasdaq has informed CNS Pharmaceuticals that the matter is now closed.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York, NY.
Key points:
- CEO John Climaco will present at the conference
- Management will be available for one-on-one meetings with qualified investors
- A video webcast of the presentation will be available on-demand from September 9, 2024, at 7:00 AM ET
- The webcast will be accessible on the Company's website and archived for 90 days
This presentation offers an opportunity for CNS Pharmaceuticals to showcase its developments and engage with the investment community.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar. The event is scheduled for Wednesday, August 28, 2024, at 3:20 PM ET.
John Climaco, the company's Chief Executive Officer, will present and discuss recent corporate developments during the webinar. This presentation offers an opportunity for investors and interested parties to gain insights into CNS Pharmaceuticals' latest advancements and future plans in the field of cancer treatment.
Participants can register for the event through the provided registration link, allowing them to join the live webcast and learn more about CNS Pharmaceuticals' innovative approaches to addressing primary and metastatic cancers in the brain and central nervous system.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in a Virtual Investor CEO Connect segment. The event, scheduled for Monday, August 26, 2024, at 12:00 PM ET, will feature CEO John Climaco.
The segment will include a brief presentation by Mr. Climaco, followed by an interactive Q&A session. Investors can submit questions live during the event or in advance via email to cnsp@jtcir.com. The live video webcast will be available on the company's website, with a replay accessible for 90 days following the presentation.
CNS Pharmaceuticals (NASDAQ:CNSP) reported its Q2 2024 financial results and provided updates on its clinical programs. Key highlights include:
1. Completion of enrollment in the potentially pivotal GBM study for Berubicin, with topline data expected in H1 2025.
2. Strategic in-licensing of TPI 287, synergistic with Berubicin, for recurrent GBM treatment.
3. Net loss of $2.5 million for Q2 2024, down from $4.0 million in Q2 2023.
4. R&D expenses decreased to $1.1 million from $2.8 million year-over-year.
5. Cash position of $1.5 million as of June 30, 2024, with additional $12.4 million raised by August 14, 2024.
The company is focused on developing novel treatments for brain and central nervous system cancers, particularly glioblastoma multiforme (GBM).
CNS Pharmaceuticals (NASDAQ:CNSP) has expanded its pipeline by in-licensing TPI 287, a late-stage, potential blood-brain barrier permeable abeotaxane for treating brain malignancies. The company obtained exclusive rights from Cortice Biosciences in exchange for 616,698 shares and potential future milestone payments. TPI 287 has shown promising results in over 350 patients, including a 60% objective response rate and 96% disease control rate in a Phase 1 study for recurrent glioblastoma (GBM). CNS plans to engage with the FDA to design a registration study for TPI 287 in recurrent GBM, aiming to start in 2025. This complements their ongoing Berubicin program, with topline results expected in H1 2025. The company also launched a new corporate brand and website to align with its focus on GBM treatment.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced that its abstract has been accepted for a poster presentation at the 2024 SNO/ASCO CNS Cancer Conference in Denver, CO. The presentation, titled 'Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin', will be delivered by Dr. Sandra Silberman, the company's Chief Medical Officer. The poster falls under the category of Research Methods and Trial Design Considerations and is scheduled for August 8, 2024, from 7:15 - 9:00 PM MT in the Plaza Exhibit Hall of the Sheraton Denver Downtown Hotel.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the Virtual Investor Closing Bell Series. The event will take place on Wednesday, June 17, 2024, at 4:00 PM ET.
CEO John Climaco will provide a corporate overview and answer questions from participants during the live video webcast. Interested parties can access the event through the Company's website, with a replay available for 90 days following the presentation.
This virtual event offers an opportunity for investors and stakeholders to gain insights into CNS Pharmaceuticals' current developments and future plans in the field of cancer treatment.
CNS Pharmaceuticals announced a registered direct offering and concurrent private placement, raising approximately $1.98 million before expenses. The company will sell 1,425,000 shares of common stock at $1.39 each, along with warrants to purchase an equal number of shares at $1.26 per share, exercisable immediately and expiring in 5 years. The closing is expected around July 5, 2024, pending customary conditions. Net proceeds will support working capital and general corporate purposes. The offering is conducted under an effective shelf registration statement and a private placement exemption.
CNS Pharmaceuticals announced a registered direct offering and concurrent private placement, selling 568,000 shares of common stock and issuing warrants for an additional 568,000 shares. The combined purchase price per share and warrant is $2.45, with warrants exercisable at $2.32. The gross proceeds are expected to be around $1.39 million before expenses.
The offering will close around June 27, 2024, pending customary conditions. Net proceeds will go towards working capital and general corporate purposes. The shares will be issued under an effective shelf registration statement filed with the SEC, while the warrants will be issued under an exemption from registration requirements.
FAQ
What is the current stock price of CNS Pharmaceuticals (CNSP)?
What is the market cap of CNS Pharmaceuticals (CNSP)?
What is CNS Pharmaceuticals' primary focus?
What is Berubicin?
What makes Berubicin different from other cancer treatments?
What stage is Berubicin currently in?
What recent achievements has CNS Pharmaceuticals reported?
Who are CNS Pharmaceuticals' key partners?
What financial steps has CNS Pharmaceuticals taken recently?
What designations has the FDA granted to Berubicin?
What is the primary endpoint of the Berubicin study?
How does CNS Pharmaceuticals ensure the accuracy and safety of its trials?
